Shen Lian Biomedical(SH:688098)2025-01-17 09:45Financial Projections - The company expects 2024 annual revenue to be approximately 303 million yuan, which is roughly flat compared to the previous year[4]. - The projected net profit attributable to the parent company for 2024 is around -45 million yuan, indicating a loss compared to a profit of 31.5 million yuan in 2023[4][5]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be approximately -49 million yuan for 2024[4]. - Excluding the impact of asset impairment, the company anticipates a net profit of approximately -21 million yuan for 2024[7]. - The financial data provided is preliminary and subject to change pending the audited annual report for 2024[9]. Market and Product Strategy - The company plans to enhance product market competitiveness and expand sales, with new products like inactivated vaccines for foot-and-mouth disease and porcine circovirus vaccines seeing increased sales proportions[6][7]. - Despite an increase in sales volume, the company faces challenges from intensified competition in the animal health industry, leading to a decline in gross margin[7]. Research and Development - The company has increased its R&D investment in 2024, focusing on developing competitive new projects and products, including progress in circular mRNA vaccine development[7]. - A provision for impairment of 28.17 million yuan has been made for certain R&D projects due to low expected future economic benefits[7].